PMVP

PMV Pharmaceuticals, Inc. (PMVP) | Rumor.io

PMV Pharmaceuticals

PMVP

Attention (50-day avg)0%

Attention rank (50-day avg)#2,497

Bullish sentiment (50-day avg)32%

Price to earnings ratio-0.93

Market capitalization72.7M

Earnings per share-1.42

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-77.7M

Social

What share of all stock conversation is about PMVP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 1

The company has presented "excellent" rezatapopt data, with a high chance of FDA approval on the first go, but faces challenges in finding other indications and managing its cash flow.
The company's recent public offering was oversubscribed, raising $50M at $1.21 per share, with a combined public offering price of $1.21 per share plus warrant, and a potential AA in 3Q27.
The company's warrants will reset to a lower price if DNA acceptance occurs, and the current cash position of the company is a significant factor in the market's reaction to the offering.

Generated by AI

Sentiment

Of the messages about PMVP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0%	27.27% -72.73	75.59% +2.66
Bearish	—	100%	72.73% +72.73	24.41% -2.66

Bullish· Sep 10

PMV Pharmaceuticals has a strong financial position with ample cash reserves, making it a valuable asset.
The company's valuation is undervalued on a liquidation/cash basis, with a price below the cash value per share.
The stock has a high potential for growth, with expected upside of 20-25% and a strong historical performance with a 31.48% gain over the past year.

Bearish· Sep 10

$PMVP's recent drop may be attributed to major holders or funds unloading their shares into liquidity, rather than just short selling.
The company's cash reserves of $183m may not be enough to sustain its operations, particularly given its burn rate and need for additional funding.
The stock's performance may be impacted by the company's Phase 2 FDA trials, which may require a full Phase 3 trial, resulting in further dilution and a longer cash runway.

Generated by AI

Topics

Of the messages about PMVP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	93.33%	95.48%
Analysts	—	—	3.33%	2.58%
Technical Analysis	—	—	3.33%	1.94%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%

Sep 10

PMV Pharmaceuticals announced promising interim data from the Phase 2 PYNNACLE trial of rezatapopt, showing a 33% overall response rate across eight different tumor types, with a 43% response rate in ovarian cancer with a TP53 Y220C mutation.
The trial's safety profile was strong, with only 3.7% discontinuation, and the company has a cash runway of over $148 million into 2026.
Analysts are bullish on the stock, with an average price target of $8.75, and some predicting a 30-40% gain, with the potential for a 50% gain if buzz grows.

Generated by AI

Community

Of the messages about PMVP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	30.34%	31.93%
Newcomers	—	100%	69.66%	68.07%

Regulars· Jun 7

The preclinical data for PMV Pharmaceuticals' PC14586 Phase 1 trial appears strong, with a potentially greater therapeutic window, and a validated approach that may translate to clinical results.
PMV Pharmaceuticals' stock price has declined significantly, hitting a new 52-week low, following the initial presentation of Phase 1 data at ASCO.
The initial PC14586 Phase 1 data presented at ASCO demonstrated anti-tumor activity across multiple solid tumor types with a p53 Y220C mutation, showing promise for PMV Pharmaceuticals' lead candidate in solid tumors.

Newcomers· Sep 1

The newcomer is concerned about the market size for Rezatapopt, a drug for the Y220C mutation, which they estimate to be around $30M/yr in the USA, and the need for finding other indications.
Poor management and the offering structure (warrants) are major concerns for the newcomer, who believes the data and high chance of FDA approval on the first go late 2027 are overshadowed by these issues.
The newcomer is excited about the significant Updated Rezatapopt Ovarian Cancer Data, which they believe is substantial enough to ignore the offering, and are eager to see the impact on the stock.

Generated by AI

Commercial leadership appointment supports launch preparation for rezatapopt Company planning NDA submission for accelerated approval of rezatapopt in patients with platinum-resistant/refractory ovarian cancer in first quarter of 2027 PRINCETON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced the appoint

22d agoYahoo Finance

PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push

PMV Pharmaceuticals Inc. (NASDAQ:PMVP) on Monday shared interim data from its Phase 2 PYNNACLE trial for rezatapopt, an investigational treatment for ovarian cancer.Based on this data, the company announced its plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of the drug.Efficacy HighlightsThe interim data, gathered up to May 14, 2026, focus on patients with platinum-resistant or refractory ovarian cancer bearing the TP53 Y220C

28d agoYahoo Finance

What's Going On With PMV Pharmaceuticals Stock Tuesday? - PMV Pharmaceuticals (NASDAQ:PMVP)

28d agoBenzinga

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities

29d agoYahoo Finance

PMV Pharma Announces Proposed Public Offering of Securities

PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, in lieu of common stock, to certain investors, pre-funded warrants to purchase shares of its

29d agoYahoo Finance

Also Discussed

Investors talking about PMVP also mention

#	Name	Attention
1	RPTX - Repare Therapeutics Inc.	——
2	Bicycle Therapeutics plc - ADRBCYC	0%0
3	Janux Therapeutics, Inc.JANX	0%0
4	ImageneBio, Inc.IKNA	0%0
5	IO Biotech, Inc.IOBT	0%0
6	Rallybio Corp.RLYB	0%0
7	ACHL - Achilles Therapeutics plc	——
8	Olema Pharmaceuticals, Inc.OLMA	0%new
9	Pliant Therapeutics Inc.PLRX	0%0
10	Relmada Therapeutics Inc.RLMD	0%0

PMV Pharmaceuticals, Inc.

Healthcare
Biotechnology

PMV Pharmaceuticals, Inc. is a precision oncology biotechnology company focused on discovering and developing small-molecule therapies that target p53 mutations in cancer. The company’s lead program, rezatapopt, is designed as a selective p53 reactivator for tumors carrying the Y220C mutation, with a tumor-agnostic approach that aims to address cancers across multiple tissue types. PMV Pharmaceuticals concentrates on translational research and clinical development for advanced solid tumors, combining drug discovery with mutation-specific biology to create targeted treatment options. Based in Princeton, New Jersey, the company operates within the broader cancer therapeutics market and is recognized for its work in mutant p53 biology and small-molecule precision medicine.

Website

Location

400 Alexander Park Drive

Princeton, NJ, 08540

United States

Social

What share of all stock conversation is about PMVP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 1

The company has presented "excellent" rezatapopt data, with a high chance of FDA approval on the first go, but faces challenges in finding other indications and managing its cash flow.
The company's recent public offering was oversubscribed, raising $50M at $1.21 per share, with a combined public offering price of $1.21 per share plus warrant, and a potential AA in 3Q27.
The company's warrants will reset to a lower price if DNA acceptance occurs, and the current cash position of the company is a significant factor in the market's reaction to the offering.

Generated by AI

Sentiment

Of the messages about PMVP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0%	27.27% -72.73	75.59% +2.66
Bearish	—	100%	72.73% +72.73	24.41% -2.66

Bullish· Sep 10

PMV Pharmaceuticals has a strong financial position with ample cash reserves, making it a valuable asset.
The company's valuation is undervalued on a liquidation/cash basis, with a price below the cash value per share.
The stock has a high potential for growth, with expected upside of 20-25% and a strong historical performance with a 31.48% gain over the past year.

Bearish· Sep 10

$PMVP's recent drop may be attributed to major holders or funds unloading their shares into liquidity, rather than just short selling.
The company's cash reserves of $183m may not be enough to sustain its operations, particularly given its burn rate and need for additional funding.
The stock's performance may be impacted by the company's Phase 2 FDA trials, which may require a full Phase 3 trial, resulting in further dilution and a longer cash runway.

Generated by AI

Topics

Of the messages about PMVP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	93.33%	95.48%
Analysts	—	—	3.33%	2.58%
Technical Analysis	—	—	3.33%	1.94%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%

Sep 10

PMV Pharmaceuticals announced promising interim data from the Phase 2 PYNNACLE trial of rezatapopt, showing a 33% overall response rate across eight different tumor types, with a 43% response rate in ovarian cancer with a TP53 Y220C mutation.
The trial's safety profile was strong, with only 3.7% discontinuation, and the company has a cash runway of over $148 million into 2026.
Analysts are bullish on the stock, with an average price target of $8.75, and some predicting a 30-40% gain, with the potential for a 50% gain if buzz grows.

Generated by AI

Community

Of the messages about PMVP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	30.34%	31.93%
Newcomers	—	100%	69.66%	68.07%

Regulars· Jun 7

The preclinical data for PMV Pharmaceuticals' PC14586 Phase 1 trial appears strong, with a potentially greater therapeutic window, and a validated approach that may translate to clinical results.
PMV Pharmaceuticals' stock price has declined significantly, hitting a new 52-week low, following the initial presentation of Phase 1 data at ASCO.
The initial PC14586 Phase 1 data presented at ASCO demonstrated anti-tumor activity across multiple solid tumor types with a p53 Y220C mutation, showing promise for PMV Pharmaceuticals' lead candidate in solid tumors.

Newcomers· Sep 1

The newcomer is concerned about the market size for Rezatapopt, a drug for the Y220C mutation, which they estimate to be around $30M/yr in the USA, and the need for finding other indications.
Poor management and the offering structure (warrants) are major concerns for the newcomer, who believes the data and high chance of FDA approval on the first go late 2027 are overshadowed by these issues.
The newcomer is excited about the significant Updated Rezatapopt Ovarian Cancer Data, which they believe is substantial enough to ignore the offering, and are eager to see the impact on the stock.

Generated by AI

PMV Pharmaceuticals

Social

Sep 1

Sentiment

Bullish· Sep 10

Bearish· Sep 10

Topics

Sep 10

Community

Regulars· Jun 7

Newcomers· Sep 1

News

PMV Pharma at H.C. Wainwright: rezafapt nears pivotal test

PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer

PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push

What's Going On With PMV Pharmaceuticals Stock Tuesday? - PMV Pharmaceuticals (NASDAQ:PMVP)

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities

PMV Pharma Announces Proposed Public Offering of Securities

Also Discussed

PMV Pharmaceuticals, Inc.

Company Information

Location

News

PMV Pharma at H.C. Wainwright: rezafapt nears pivotal test

PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer

PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push

What's Going On With PMV Pharmaceuticals Stock Tuesday? - PMV Pharmaceuticals (NASDAQ:PMVP)

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities

PMV Pharma Announces Proposed Public Offering of Securities

Also Discussed

Social

Sep 1

Sentiment

Bullish· Sep 10

Bearish· Sep 10

Topics

Sep 10

Community

Regulars· Jun 7

Newcomers· Sep 1